Design Therapeutics Overview

  • Status
  • Public

  • Employees
  • 60

Employees

  • Stock Symbol
  • DSGN

Stock Symbol

  • Share Price
  • $9.02
  • (As of Friday Closing)

Design Therapeutics General Information

Description

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6005 Hidden Valley Road
  • Suite 110
  • Carlsbad, CA 92011
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 6005 Hidden Valley Road
  • Suite 110
  • Carlsbad, CA 92011
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Design Therapeutics Stock Performance

As of 20-Nov-2026, Design Therapeutics’s stock price is $9.02. Its current market cap is $578M with 64M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.02 $9.32 $7.82 - $17.25 $578M 64M 555K -$1.20

Design Therapeutics Financials Summary

As of 30-Sep-2026, Design Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 581,917 330,093 97,800 (139,316)
Revenue 0 0 0 0
EBITDA (81,682) (78,845) (61,787) (77,653)
Net Income (74,086) (69,792) (49,588) (66,862)
Total Assets 216,808 226,203 252,093 289,643
Total Debt 2,514 1,535 2,334 3,050
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Design Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Design Therapeutics‘s full profile, request access.

Request a free trial

Design Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Design Therapeutics‘s full profile, request access.

Request a free trial

Design Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC
Drug Discovery
Carlsbad, CA
60 As of 2026

South San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Design Therapeutics Competitors (43)

One of Design Therapeutics’s 43 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Beam Therapeutics Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Lisata Therapeutics Corporation Basking Ridge, NJ
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 43 competitors. Get the full list »

Design Therapeutics Patents

Design Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213229-A1 Methods and compounds for treating genetic disease Pending 01-Apr-2025
WO-2026107489-A1 Soluble formulations Pending 18-Nov-2024
WO-2026107406-A1 P53 heterobifunctional conjugates and uses thereof Pending 15-Nov-2024
WO-2026015815-A1 Methods of treating haploinsufficiency disorders Pending 12-Jul-2024
AU-2024394822-A1 Compounds and methods for treating sickle cell disease Pending 08-Dec-2023 C07D401/14
To view Design Therapeutics’s complete patent history, request access »

Design Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Design Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Design Therapeutics‘s full profile, request access.

Request a free trial

Design Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Design Therapeutics’s complete esg history, request access »

Design Therapeutics FAQs

  • Where is Design Therapeutics headquartered?

    Design Therapeutics is headquartered in Carlsbad, CA.

  • What is the size of Design Therapeutics?

    Design Therapeutics has 60 total employees.

  • What industry is Design Therapeutics in?

    Design Therapeutics’s primary industry is Drug Discovery.

  • Is Design Therapeutics a private or public company?

    Design Therapeutics is a Public company.

  • What is Design Therapeutics’s stock symbol?

    The ticker symbol for Design Therapeutics is DSGN.

  • What is the current stock price of Design Therapeutics?

    As of 20-Nov-2026 the stock price of Design Therapeutics is $9.02.

  • What is the current market cap of Design Therapeutics?

    The current market capitalization of Design Therapeutics is $578M.

  • Who are Design Therapeutics’s competitors?

    NGM Biopharmaceuticals, Beam Therapeutics, CRISPR Therapeutics, Lisata Therapeutics, and Capricor Therapeutics are some of the 43 competitors of Design Therapeutics.

  • What is Design Therapeutics’s annual earnings per share (EPS)?

    Design Therapeutics’s EPS for 12 months was -$1.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process